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ABSTRACT
Isolation and Host Range of Staphylococcus aureus Bacteriophages
and Use for Decontamination
of Fomites
Kyle C. Jensen
Department of Microbiology and Molecular Biology, BYU
Master of Science

Staphylococcus aureus is a common bacterium found on the skin and mucosal
membranes of about 20% of the population. S. aureus growth on the skin is harmless, but if it
bypasses the skin it can causes life-threatening diseases such as pneumonia, meningitis,
bacteremia, and sepsis. Antibiotic-resistant strains of S. aureus, called Methicillin Resistant S.
aureus (MRSA), are resistant to most antibiotics except vancomycin. However, vancomycin
resistant strains of MRSA are becoming more common. In this study, 12 phages were isolated
capable of infecting human S. aureus and/or MRSA strains. Five phages were discovered
through mitomycin C induction of prophages and seven phages were found through enrichment
of environmental samples. Primary S. aureus strains were also isolated from environmental
sources to be used as tools for phage discovery and isolation as well as to examine the target cell
host range of the phage isolates. S. aureus isolates were tested for susceptibility to oxacillin in
order to determine methicillin-resistance. Experiments were performed to assess the host range
and killing potential of newly discovered phage. The M1M4 phage had the broadest host range
and lysed 12% of the S. aureus strains that were tested. The host ranges were reinforced by
spectrophotometric assay data which showed a reduction in bacterial optical density of 1.3 OD600.
The phages were used to decontaminate MRSA from fomites (glass and cloth) and successfully
reduced colony forming units by 1-2 logs, including tests of a phage cocktail against a cocktail of
MRSA isolates. Our findings suggest that phage treatment can be used as an effective tool to
decontaminate human MRSA from both hard surfaces and fabrics.

Key words: Staphylococcus aureus, methicillin-resistant Staphylococcus aureus,
bacteriophage, phage therapy

Table of Contents
Title Page ......................................................................................................................................... i
Abstract ........................................................................................................................................... ii
Table of Contents ........................................................................................................................... iii
List of Tables ................................................................................................................................. vi
List of Figures ............................................................................................................................... vii
Introduction ..................................................................................................................................... 1
Staphylococcus aureus ................................................................................................................ 2
Methicillin-Resistant Staphylococcus aureus ............................................................................. 5
Bacteriophage .............................................................................................................................. 9
MRSA Bacteriophage ............................................................................................................... 12
Materials and Methods .................................................................................................................. 15
Media......................................................................................................................................... 15
S. aureus Isolation ..................................................................................................................... 15
Phage Isolation .......................................................................................................................... 16
Temperate Phage Induction ................................................................................................... 16
Virulent Phage Isolation ........................................................................................................ 17
High Titer Phage Lysates ...................................................................................................... 17
Host range ................................................................................................................................. 18
Spot Test ................................................................................................................................ 18
iii

Spectrophotometric Assays ................................................................................................... 18
Decontamination Assays ........................................................................................................... 19
Cloth decontamination ........................................................................................................... 19
Glass coverslip decontamination ........................................................................................... 19
Results ........................................................................................................................................... 21
Publication................................................................................................................................. 21
Abstract ..................................................................................................................................... 21
Introduction ............................................................................................................................... 22
Materials and Methods .............................................................................................................. 24
Isolation of Staphylococcus aureus strains ............................................................................ 24
Isolation of bacteriophage ..................................................................................................... 25
Virulent phage isolation......................................................................................................... 25
Temperate phage isolation ..................................................................................................... 26
Host range analysis ................................................................................................................ 27
Spot testing ............................................................................................................................ 27
Spectrophotometric assay ...................................................................................................... 27
Decontamination assays ........................................................................................................ 28
Glass coverslip decontamination ........................................................................................... 28
Cloth decontamination ........................................................................................................... 28
Statistical analysis.................................................................................................................. 29
iv

Ethics Statement .................................................................................................................... 29
Results ....................................................................................................................................... 30
Isolation of S. aureus strains.................................................................................................. 30
Isolation of bacteriophage ..................................................................................................... 32
Assessment of host range of phage isolates........................................................................... 34
Assessment of phage ability to decontaminate fomites ......................................................... 38
Discussion ................................................................................................................................. 44
Acknowledgments ................................................................................................................. 46
Discussion ..................................................................................................................................... 47
References ..................................................................................................................................... 53
Appendix ....................................................................................................................................... 69

v

List of Tables
Table 1 Staphylococcus aureus strains. ........................................................................................ 31
Table 2 Phage Strains.................................................................................................................... 33
Table 3 Phage Host Range……………………………………………………………………….35

vi

List of Figures
Figure 1 MRSA routes of transmission .......................................................................................... 4
Figure 2 MRSA routes of transmission .......................................................................................... 4
Figure 3 MRSA routes of transmission .......................................................................................... 7
Figure 4 Bacteriophage morphology ............................................................................................ 11
Figure 5 Assessment of host range .............................................................................................. 37
Figure 6 Decontamination of lab coats and glass coverslips ....................................................... 41
Figure 7 Decontamination with a phage cocktail ........................................................................ 43
Supplementary Figure 1 Time course decontamination ................................................................... 69

vii

Introduction
Staphylococcus aureus infections are the most frequent hospital-acquired infections
reported in developed countries [2]. S. aureus is a gram positive coccus commonly found
colonizing the skin and mucosal membranes of humans and many livestock species [3, 4]. S.
aureus is very specialized in its ability to colonize and infect humans with an average of 38
different proteins specifically for host innate immune evasion [5]. These immune evasion
mechanisms allow S. aureus to be more opportunistically effective as a pathogen. MethicillinResistant S. aureus (MRSA) is a variant of S. aureus resistant to methicillin and is responsible
for more than 50% of S. aureus infections in European intensive care units [6]. Recently MRSA
strains have become more common in community settings and more difficult to treat due to
increasing levels of multiple-antibiotic resistance [6-8].
Bacteriophages (phages) are viruses capable of infection and replication in bacterial cells.
Phages are the most abundant biological entity found on the planet and as such represent a huge
portion of the world’s genetic diversity [9, 10]. They also represent a huge—mostly untapped—
source of new genes and protein products with potential use as medical treatments [11]. Phages
discovered in 1915 were quickly commercialized and used for medical phage therapy. Early
phage therapy was fraught with many problems: purifying phage treatments, exaggerated healing
claims, and a failure to scientifically prove efficacy [12]. These problems, plus a lack of funding
during World War II and the invention of the easily usable antibiotic penicillin, caused most
scientists to abandon phage research in favor of pursuing new antibiotics. Recent increases in
multi-antibiotic-resistant bacterial infections have begun to renew interest in phage therapy [13].
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The purpose of this introduction is to provide a foundation for the significance S. aureus
plays in nosocomial infections, community-associated colonizations, and the difficulties in
treating MRSA infections. It will also introduce phages as a potential source of bactericidal
treatments for MRSA-contaminated fomites.
Staphylococcus aureus
S. aureus colonizes 20% of the human population, and can persist anywhere between 70
days to more than 8 years [14, 15]. S. aureus growth on the skin and mucous membranes is
harmless, but if it bypasses the skin it can cause life-threatening diseases such as skin and soft
tissue infections, bacteremia, sepsis and endocarditis [16]. Immune evasion mechanisms such as
protein A inactivate immunoglobulin by binding to the Fcγ domain and thus disable complement
fixation, and enable S. aureus to become more virulent and fit [17]. S. aureus bacteremia
mortality rate is 43% [16, 18]. S. aureus infections are the most commonly acquired nosocomial
infections [19]. These infections can occur in many different tissue types including bones, joints,
blood, lungs, heart, and brain. Those who are immunocompromised are more susceptible to
these dangerous infections [20]. In 2005, approximately 11,000 deaths were attributed to S.
aureus in the United States [21].
Livestock are also commonly colonized and infected with S. aureus [7, 22-24]. Bovine
mastitis in cattle is the most well-known disease caused by S. aureus, infecting the udder and
inducing inflammation [23]. The indirect cost of bovine mastitis is difficult to calculate, but
direct costs in the U.S. are estimated at $1.7-2 billion [25, 26]. S. aureus also causes disease in
poultry such as bacterial chondronecrosis, which causes lameness in chickens [27]. Studies have
shown that S. aureus jumped from humans to poultry approximately 38 years ago and has since
become a near ubiquitous in poultry flora [27]. During the butchery process S. aureus flora are
2

released contaminating the raw poultry. For instance, 77% of raw turkey and 41% of raw
chicken is contaminated with these bacteria [28]. Handling contaminated raw meat is another
route of transmission for S. aureus to enter the community [29]. Livestock-associated S. aureus
strains have been shown to move from animals to humans. This is exemplified by MRSA
sequence type 398 which moved from pigs to humans in the early 2000s and now colonizes
many humans worldwide [23, 24].
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Figure 1: Structure of penicillin and methicillin
Penicillin (A) and methicillin (B) are both β-lactam antibiotics. Here the structure
of both is shown. The active region on both molecules is the β-lactam ring which
competitively binds to DD-transpeptidase and is the site where penicillinase
cleaves penicillin.

Figure 2: Transpeptidase catalysis of peptidoglycan
DD-transpeptidase assists in synthesizing new peptidoglycan by crosslinking the
enzyme-OH to the D-Ala-D-Ala end of the peptidoglycan chain releasing one of
the D-Ala residues. The enzyme then covalently binds the peptidoglycan chain
with an adjacent chain at the Gly residue and releases the enzyme. β-lactam
antibiotics mimic the D-Ala-D-Ala region of peptidoglycan and competitively
bind DD-transpeptidase
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Methicillin-Resistant Staphylococcus aureus
β-lactam antibiotics function through the binding of the four-membered β-lactam ring to
the bacterial enzyme DD-transpeptidase [30]. DD-transpeptidase assists in synthesizing new
peptidoglycan by crosslinking the enzyme-OH to the D-Ala-D-Ala end of the peptidoglycan
chain releasing one of the D-Ala residues [31]. The enzyme then covalently binds the
peptidoglycan chain with an adjacent chain at the Gly residue and releases the enzyme (Fig. 2).
β-lactam antibiotics mimic the D-Ala-D-Ala region of peptidoglycan, and competitively bind
DD-transpeptidase (Fig. 1A) [30, 31]. Cell death occurs because of an imbalance between cell
wall production and natural degradation. Penicillinases are enzymes which confer penicillinresistance. The enzyme cleaves the β-lactam ring of β-lactam antibiotics thus preventing cell
death [32]. Methicillin is a penicillinase-resistant β-lactam antibiotic created in response to
penicillin-resistance [32]. Methicillin has a similar mode of action as other β-lactams, but is
unaffected by penicillinases because of stoichiometric interference (Fig 1B) [33].
Methicillin-resistant isolates of S. aureus were isolated in British hospitals in 1959, only
two years following the introduction of methicillin [34]. Methicillin-resistant S. aureus (MRSA)
resists methicillin by employing a new transpeptidase with a low affinity for penicillinaseresistant β-lactams [35]. The mecA gene encodes for the new transpeptidase, commonly known
as Penicillin-Binding Protein 2A (PBP2A). PBP2A replaces the function of the original
transpeptidase and, because PBP2A has low affinity for β-lactams, it is unaffected by methicillin
[36]. The original copy of the mecA gene is hypothesized to have come from Staphylococcus
fleurettii, which contains a chromosomal copy of mecA, but has none of the other genes usually
associated with S. aureus mecA [37].
5

In addition to methicillin-resistance, many MRSA strains are resistant to nafcillin,
tobramycin, gentamicin, amikacin, cefoxitin, clindamycin, erythromycin, and chloramphenicol
[38-40]. In the past antibiotic resistance was not considered a significant problem because new
antibiotics were introduced to counter resistant bacterial strains. After the initial flurry of
antibiotic discovery in the 1960s, new antibiotic derivatives have been slow in their creation, and
almost no new antibiotics with novel mechanism have been discovered [41]. The lack of novel
antibiotics has increased the difficulty in treating multi-antibiotic bacterial strains [42].
MRSA easily moves between different reservoirs causing community-associated MRSA
(CA-MRSA) and hospital-associated-MRSA (HA-MRSA) interchange to occur often (Fig. 3)
[24]. MRSA isolates becoming resistant to antibiotics have been shown to occur in both the
hospital and on livestock farms [43-45]. In both settings, MRSA antibiotic resistances can
quickly spread. MRSA colonizing livestock can transfer to the community through farm workers
working closely with the animals, or through butchers working with raw meat contaminated with
MRSA [46, 47]. Once in the community, MRSA can cause infections which often leading to
hospitalization and potentially introducing the new strain to other patients as a nosocomial
infection [48]. CA-MRSA infections are quickly increasing and changing the dynamics of
MRSA infections [48]. This changing dynamic is alarming because of the few new antibiotics
created to stop these infections. As an alternative to discovering new antibiotics, many scientists
have begun investigating phages as a medical treatment for MRSA [49].
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Routes of Transmission

Figure 3 MRSA Routes of Transmission
MRSA is uniquely able to colonize many different host organisms. MRSA strains often transfer
from one organism to another. CA-MRSA can easly move from farms to the community via raw
meat and farm workers. From the community MRSA is then easily introduced into the hospitals.
The movement of MRSA is dynamic and can flow in nearly every direction [18].
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Between the years of 2003 to 2008, MRSA deaths in the U.S. doubled, outnumbering the
combined mortality rate from HIV-positive and influenza hospital patients [50]. In 2011, 80,461
people in the United States were diagnosed with a MRSA infection and about 19,000 died due to
the infection [51]. Despite the increasing difficulty in treating MRSA infections, hospitals have
increased their efforts at controlling MRSA, decreasing the overall rates of MRSA in the United
States and in Europe decreasing [6, 52]. Despite nosocomial infection decreases CA-MRSA
infections are becoming increasingly more common outside the hospital [48]. CA-MRSA have
distinct lineages from HA-MRSA and can be differentiated from nosocomial infections [48].
USA300 and USA400 are the most common CA-MRSA strains in the U.S. [53]. HA-MRSA and
CA-MRSA infections are increasingly being treated with vancomycin. The increased use of
vancomycin raises concerns that vancomycin-resistance well be increasingly selected for
creating vancomycin-resistant S. aureus (VRSA) more often [54]. Vancomycin is one of a few
antibiotics available to treat MRSA. Despite worldwide distribution of VRSA, isolates are still
rare [55, 56].
Fomite contamination in hospitals is a large source of nosocomial infections [57]. MRSA
from serum contaminating surfaces is detectable for 41 days on glass, 45 days on tile, and greater
than 60 days on countertops [58]. S. aureus remained viable on cleaning cloths for 24 hours and
were transferred to objects it touched [59]. In the community MRSA regularly moves from
person to person, or fomite to person. Everyday items, such as computers and basketballs, act as
a fomite reservoir for MRSA with 2 of 24 public computer keyboards being contaminated with
MRSA [60]. The use of a cleansing wipes to decontaminate a fomite does not guarantee sterility.
Fomites inoculated with 109 CFUs S. aureus and cleaned with disinfecting wipes only reduced
bacterial CFUs by 4.5 logs leaving 105 viable S. aureus cells, enough to cause infection [61].
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Bacteriophages
Estimates place the population of phage worldwide at about 1031 particles [10]. Phages
are viruses capable of infecting bacteria, and as such are obligate parasites using the cellular
machinery to create new phage particles [12, 62]. Phages use the host machinery to either
produce a lytic or a lysogenic infection. Lytic infections immediately move to phage replication
and lysis of the bacterial cell. Phage induced cell lysis represent a significant force on bacterial
populations being implicated in approximately 20-90% of bacterial deaths [63]. Phage infections
can follow one of two paths. Virulent infections immediately move to phage participle
replication and lysis of the host cell. Temperate phages integrate the phage genome into the host
chromosome creating a prophage. It then waits until conditions are right to resume a lytic
infection and escape from the host. Of the two types of phage infection lytic phage are more
efficient for medical treatments due to their immediate lysing of bacterial cells [64].
Phages were first discovered around the turn of the 20th century and initially studied for
their anti-bacterial capabilities. D’Herelle was one of the first scientists to use phages as an
antimicrobial. He administered phages to a boy with dysentery and within 24 hours the boy
began to recover [65]. In addition, d’Herelle administered phage to three more patients with
dysentery, all who subsequently began to recover. However, before d’Herelle published his
experiments regarding phage treatments, Richard Bruynoghe and Joseph Maisin used phage to
successfully treat a patient with a staphylococcal skin infection, somewhat obscuring d’Herelle’s
work at the time [12]. With the discovery of penicillin, and subsequent antibiotics, Western
science turned away from phage therapy largely in favor of the more convenient antibiotics [12].
Despite Western science’s abandonment of phage therapies, Eastern European scientists
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continued using medical phage therapy [66, 67]. With the emergence of multi-antibiotic-resistant
bacteria Western scientists have finally begun to renew their interest in phage [13, 68, 69].
One of the greatest advantages offered by phages is the coevolution between phages and
host bacteria, which allows phages to infect resistant host strains [70, 71]. Werts et al. used
phage lambda to show phage/E. coli coevolution. Phage lambda’s protein J uses the E. coli cell
receptor protein LamB to attach. Treating E. coli with phage lambda increased selective pressure
for lamB mutations in order for E. coli to escape phage attachment. In turn this introduces
selective pressure for lambda protein J mutants to coevolve and bind to the new LamB receptor
[72]. Additional studies have shown that bacteria can quickly become resistant to current
populations of phages. Phages then face increased selection for phage mutants with infectivity
for the new strain of bacteria, and have been shown to increase infectivity to all past strains of
the bacterium [73].
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Bacteriophage Morphology

Figure 4 Phage Morphology
Phage morphology comes in many unique varieties. S. aureus phages are usually one of three
classes: Myoviridae, Siphoviridae, and Podoviridae. As such most are also double stranded DNA
phage. It is thought the most clinically relevant strains of phage are the Myoviridae class because
of their inability to enter the lysogenic cycle. Image from H.-W. Ackermann’s review [1]
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MRSA Bacteriophage
Phages have many different morphological types. Their genomes are usually composed
of dsDNA but occasionally are ssDNA, ssRNA, or dsRNA [1]. Though there are more phage
categories, S. aureus phages are generally separated into one of three different dsDNA classes:
Podoviridae, Siphoviridae, and Myoviridae (Fig. 4). Podoviridae have short tails and genomes
of approximately 20kb. Siphoviridae are non-contractile tailed phage and have genomes of
approximately 50kb. Myoviridae class phages have contractile tails consisting of a sheath and a
central tube and genomes of greater than 125 kb. Myoviridae S. aureus phages are also obligate
virulent and are hypothesized to be more useful for medical phage therapy [1, 74].
There are several obstacles to overcome before medical phage therapy can become a
viable treatment. Those obstacles include limited phage host range, possible carriage of bacterial
virulence genes, temperate phage induced protection of the bacterial cell from other phage lysing
the cell and immunogenicity. Phage host range is defined as the number of bacterial host strains
the phage infects. Phage host ranges vary dramatically between phage strains. Medical phage
therapy can adapt to limited host range by using a cocktail of phage with a combined larger host
range. A phage’s host range can be increased through passaging in the presence of resistant
bacterial strains [75, 76]. After successive rounds of replication, mutant phages with infectivity
towards the resistant bacterial strain are selected. Temperate phages present multiple problems
due to their ability to enter the lysogenic cycle. During this cycle the phage integrates its
genome into the host DNA, often introducing virulence factors and phage resistance mechanisms
into the host bacterium [77, 78]. Many virulence factors attributed to S. aureus are actually
phage encoded, such as Panton-Valentine leukocidin, staphylokinase, enterotoxin A and Toxic
Shock Syndrome Toxin 1 [79]. Virulence factors benefit both the S. aureus host and phage by
12

increasing the fitness of S. aureus inside a human host. In return the prophage multiplies along
with its bacterial host. Lysogens also increase host fitness by introducing phage-resistance to the
prophage. These mechanisms are classified as abortive infection, adsorption inhibition, injection
blocking, or restriction/modification systems [78]. Phage antibacterial effects are also
dramatically affected by antibodies, which cause a loss of antibacterial effect [80]. Phage
immunogenicity is an important issue which dictates the success or failure of phage therapy [81].
In addition, natural bacterial flora contributes to phage immunogenicity because antibodies are
created as a result of contact with natural phages which infect the natural flora. This natural
vaccine creates antibodies against phages which may be used in phage therapy, limiting the
therapy’s efficacy [82]. In fact, phage immunogenicity is being taken advantage of in current
research using phage as a vehicle for HIV proteins in an attempt to create a HIV vaccine [83].
Despite the enormous obstacles to overcome, phage therapy has been successfully used by
Eastern European countries and is still used with great success today [84].
S. aureus can remain on a hard surface for three months and on for fabric three weeks
[85]. Hard surfaces can easily transmit S. aureus to skin for at least 70 days post inoculation [86].
Effective reductions in S. aureus nosocomial infections require hospitals to carefully manage
fomite decontamination. Phages are a natural decontaminator; therefore several studies have
used phages to quantify phage-mediated fomite decontamination. Decontamination using phage
was shown to be viable in two studies attempting to remove Yersinia pestis or Listeria
monocytogenes from hard surface fomites. Each study showed bacterial load reductions of
between 3.5-5 logs [87, 88].
The purpose of this research was to isolate phages which can be used to reduce MRSA
loads on fomites. With this in mind, a three aim plan was created to accomplish this goal: 1) to
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isolate phages and purify them into single strains; 2) Identify the host range and lytic efficiency
of each of the phages; and 3) to perform experiments testing decontamination efficacy of the
phages. Herein is described the isolation of 12 phages with lytic activity against MSSA and
MRSA isolates. The M1M4 phage had the broadest host range and lysed 12% of the S. aureus
strains it was tested against. Spectrophotometry assay results reinforced the host range results
and showed reductions of cellular densities of about 1.3 OD600 for most phage tested.
Decontamination of fomites (glass and cloth) yielded between one and two log reductions in
MRSA colony forming units.
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Materials and Methods
Media
Bacterial cultures were grown in LB, LB broth supplemented with magnesium and calcium (LBMC), LB-MC top agar, or Mannitol Salt Agar. LB broth contained the following: 1% tryptone,
0.5% yeast extract, 0.5% NaCl, 0.1% 2 N NaOH and was sterilized by autoclaving for one hour.
LB agar was prepared as LB broth above with the addition of 1.2% agar. LB-MC was prepared
similar to the LB broth above. However, after autoclaving sterile 4mM MgCl2 and 4mM CaCl2
was added. LB-MC top agar was prepared as LB agar with a reduction of agar to 0.4% and
supplemented with sterile 4mM MgCl2 and 4mM CaCl2.
Mannitol Salt Agar was purchased from Fluka Analytical and contained 1.0% D-mannitol, 0.1%
meat extract, 1.0% peptone, 0.0025% phenol red, 7.5% NaCl, and 1.5% agar and was sterilized
by autoclaving for one hour.
Phage Buffer was used to for storage of phage particles. It contained 500ml ddH2O, (100mM)
2.92 g NaCl, (10mM) 1.016g MgCl26H2O, (50mM) 3.94 g Tris-HCl, (0.01%) 50 mg gelatin. pH
was adjusted to 7.5 and the phage buffer was autoclaved for one hour.
S. aureus and Methicillin-Resistant S. aureus Isolation
Samples were taken from locations commonly associated with S. aureus: athletic facilities,
hospitals, nasal swabs, chicken coups, raw meat, and from collaborators. S. aureus was selected
for by adding equal an amount 2X LB broth to wet samples and suspending dry samples in LB
broth and thoroughly vortexing to remove S. aureus cells. A MSA plate was spotted with 10µL
of a sample, streaked to isolation and incubated at 37°C for 48h. Fermentation positive colonies
15

were further tested by Gram stain, catalase testing, and coagulase tube tests to confirm isolation
of S. aureus (Gram positive cocci which is positive for catalase, coagulase and mannitol
fermentation). Methicillin-resistance was determined by plating on MSA plates with 2µg/mL
oxacillin, followed by incubation at 37°C for 48h (note that oxacillin-resistance is considered to
be equivalent to methicillin-resistance in many studies; [89, 90]). Additional strains were
acquired from the American Type Culture Collection (Manassas, VA, USA) and from BEI
Resources (Manassas, VA) (table 1).
Phage Isolation
Temperate Phage Induction
S. aureus was inoculated into LB broth and grown overnight at 37°C at 200rpm. The overnight
culture was used to inoculated four hour cultures S. aureus sub-cultures grown for 30 min at
37°C at 200rpm (insuring log phase growth), followed by exposure to mitomycin C (SigmaAldrich) at 0.5μg/mL for 8h at 37°C. Cells were pelleted by centrifugation at 3000xg for 10 min
and supernatants passed through a 0.45μm filter and stored at 4°C until plaque assays were
performed. 100µL of phage sample was added to 100µL of bacteria and incubated overnight at
37°C before adding to molten LB top agar for plaque production. To purify the phage into single
strains isolated plaques were picked and crushed to release phage particles and re-inoculated
onto S. aureus. Positive plaque forming samples were repicked and overlaid three successive
rounds to purify phage into single strain isolates. The bacterial strain used to isolate each phage
is indicated in Table 2.
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Virulent Phage Isolation
Environmental samples were obtained and stored at 4°C until phage enrichment could be
performed. LB broth was added to dry samples and thoroughly vortexed to dislodge phage
particles. An equal volume of 2x LB broth was added to liquid samples. All samples were then
filtered using 0.45µm filters to remove bacteria. Five different strains of S. aureus four hour
cultures were combined: M1, M5, S. aureus 29213, DH1 and HA1 (see Table 1), to which the
filtrate was added. The enrichment samples were incubated overnight at 37°C shaking at
60rpm. The overnight enrichment was centrifuged at 5,000xg for 12 min to pellet bacteria, and
then filtered using a 0.45µm filter. A bacterial overlay was created by mixing 100µl four hour S.
aureus culture into 3ml molten LB-MC top agar and poured over a LB agar plate. Once
solidified 10µl of enrichment was spotted on the overlay and dried. The overlay was incubated
overnight at 37°C. Each overlay was inspected for plaque formation in the area where samples
were spotted. All plaques were picked and mixed in 3ml molten LB-MC top agar with 100µl S.
aureus and overlaid on LB agar. Positive plaque forming samples were repicked and overlaid
three successive rounds to purify phage into single strain isolates. The bacterial strain used to
isolate each phage is indicated in Table 2.
High Titer Phage Lysates
High titer phage lysates were prepared by adding 100µl host bacteria and varying amounts of
phage lysate into 3ml molten LB top agar and overlaid onto LB agar plates. Overlays with near
complete lysis, or a webbed plaque distribution, were treated with 4ml of phage buffer and the
top agar overlay was crushed, followed by 90 min incubation at room temperature. Phage buffer
was removed and centrifuged at 5,000rpm for 10 min and filtered at 0.45μm to remove bacterial
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cells, then stored at 4°C with chloroform. Phage stocks were tittered by serial dilution and
plating similarly described above.
Host range
Spot Test
Overnight cultures were prepared in LB broth and then sub-cultured by addition of
100µL to 3ml LB broth and grown at 37°C for 90 min. 100µL of sub-culture was inoculated into
3mL of molten LB top agar and overlaid onto LB agar plates. Each overlay was allowed to
solidify for 15min. All phage lysates (original titers approximately 108pfu/mL) were diluted in
10 fold increments and 10µL of each dilution was spotted onto the bacterial overlay [91], dried,
then incubated at 37°C overnight. As a control, each bacterial strain was also mock infected with
sterile phage buffer. Results were analyzed based on detection of any lysis and further dilutions
were checked for single plaques to ensure phage lysis rather than bacteriocin induced lysis. All
spot tests were repeated in triplicate to confirm results.
Spectrophotometric Assays
500µl of S. aureus overnight culture was used to inoculate 3ml LB-MC broth and incubated at
37°C with 200rpm shaking, until the culture reached an optical density (O.D.) of 1.40, between
2.5-3h post inoculation. A high titer phage lysate was diluted with phage buffer to a
concentration of 108 pfu/ml. 100µl phage and 20µl bacteria were inoculated into 3.5ml LB broth.
For use as a control a parallel mock treated run was also performed using sterile phage buffer.
Samples were removed at 2, 3, and 4 hours post infection and an OD600 was measured (Ultraspec
10 spectrophotometer, Amersham Biosciences, Piscataway, NJ, USA) using sterile LB broth as a
blank. All experiments and mock treatments were run in triplicate.
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Decontamination Assays
Cloth decontamination
To mimic the condition where nosocomial infections may occur, we used lab coat material
composed of 35% cotton and 65% polyester as a fomite. 1.5 x 1.5cm pieces of lab coat material
were cut and autoclaved to achieve sterility. Four hour sub-cultured MRSA samples were
diluted 1:104 and 100µL was inoculated onto the lab coat and allowed to remain for 30 min at
37°C. The initial bacterial load inoculated and subsequently recovered from untreated cloth was
~1-5x106 Colony Forming Units (CFU). 100µL of phage lysate was then added and incubated at
37°C for 30min. Phage titers added to the cloth ranged from 1x107 to 1x108 PFU for a range of
multiplicity of infection of 200 to 50,000. As a control, sterile phage buffer instead of phage
lysate was added as a mock treatment. Viable bacteria were removed by placing the cloth into
500µL LB broth followed by vortexing at high speed for 10s. 10µl of the broth was serially
diluted, then another 10µl was spotted onto an LB agar plate and incubated at 37°C overnight;
colonies were counted the next morning. Colony-forming units were calculated for both mocktreated and phage treated. Mock-treated bacterial loads were then divided by phage-treated in
order to determine the decontamination capability of the phage. These assays were performed in
triplicate.
Glass coverslip decontamination
To mimic conditions possibly more suitable to phage decontamination we performed
decontamination assays using glass coverslips. 22 x 22 mm glass coverslips were used to test
decontamination on hard surfaces. 10µL of sterile milk was spread onto the sterile coverslip
surface and dried, giving the coverslips a better surface for bacterial adherence [88]. The test
MRSA strain was sub-cultured for 4h at 37°C, with 200rpm shaking, to achieve logarithmic
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growth and then diluted 1:103, giving a final concentration of approximately 106 cfu/mL. 10µL
of the cell culture was spread onto the coverslips and incubate at room temperature for 30 min.
Coverslips were then treated with 100µL of phage lysate at a multiplicity of infection of 200 to
50,000 and incubated at room temperature for 30min. As a control, sterile phage buffer instead
of phage lysate was added as a mock treatment. Viable bacteria were removed by placing the
coverslip into 500µL LB broth followed by vortexing at high speed for 10 seconds. 10µl of the
broth was serially diluted, then another 10µl was spotted onto an LB agar plate and incubated at
37°C overnight; colonies were counted the next morning. Colony-forming units were calculated
for both mock-treated and phage treated. Mock-treated bacterial loads were then divided by
phage-treated in order to determine the decontamination capability of the phage. These assays
were performed in triplicate.
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Isolation and Host Range of Bacteriophage with Lytic Activity against MethicillinResistant Staphylococcus aureus and Potential use as a Fomite Decontaminant
Kyle C. Jensen, Bryan B. Hair, Trevor M. Wienclaw, Mark H. Murdock, Jacob B. Hatch, Aaron
T. Trent, Tyler D. White, Kyler J. Haskell, and *Bradford K. Berges
In lieu of the results section I have included a first author publication containing the results of the
previously described experiments. The publication was accepted to PLoS One on June 9, 2015.
Abstract
Staphylococcus aureus is a commensal bacterium and opportunistic pathogen commonly
associated with humans and is capable of causing serious disease and death including sepsis,
pneumonia, and meningitis. Methicillin-resistant S. aureus (MRSA) isolates are typically
resistant to many available antibiotics with the common exception of vancomycin. The presence
of vancomycin resistance in some S. aureus isolates combined with the current heavy use of
vancomycin to treat MRSA infections indicates that MRSA may achieve broad resistance to
vancomycin in the near future. New MRSA treatments are clearly needed. Bacteriophages
(phages) are viruses that infect bacteria, commonly resulting in death of the host bacterial
cell. Phage therapy entails the use of phage to treat or prevent bacterial infections. In this study,
12 phages were isolated that can replicate in human S. aureus and/or MRSA isolates as a
potential way to control these infections. 5 phages were discovered through mitomycin C
induction of prophage and 7 others as extracellular viruses. Primary S. aureus strains were also
isolated from environmental sources to be used as tools for phage discovery and isolation as well
as to examine the target cell host range of the phage isolates by spot testing. Primary isolates
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were tested for susceptibility to oxacillin in order to determine which were MRSA. Experiments
were performed to assess the host range and killing potential of newly discovered phage, and
significant reductions in bacterial load were detected. We explored the utility of some phage to
decontaminate fomites (glass and cloth) and found a significant reduction in CFUs of MRSA
following phage treatment, including tests of a phage cocktail against a cocktail of MRSA
isolates. Our findings suggest that phage treatment can be used as an effective tool to
decontaminate human MRSA from both hard surfaces and fabrics.

Introduction
Staphylococcus aureus infections are the most frequent type of hospital-acquired
infections reported in developed countries [2]. S. aureus is a common commensal bacterium
capable of colonizing the nose and skin and is found transiently in ~50% of the human
population and ~20% permanently [3, 92]. Nasal colonization has been linked to surgical site
infections [93] and S. aureus can cause life-threatening diseases in many different tissue types
including bones, joints, blood, lungs, heart, and brain [16]. S. aureus is the bacterium most
commonly associated with bloodstream, soft tissue, lung and skin infections [94]. Many of these
infections are treated using antibiotics; however, bacterial evolution has resulted in strains of S.
aureus resistant to multiple antibiotics.
Methicillin Resistant Staphylococcus aureus (MRSA) represents a group of S. aureus
isolates commonly resistant to methicillin as well as erythromycin, levofloxacin, tetracycline,
clindamycin, mupirocin, gentamicin, trimethoprim, and/or doxycycline but is typically
susceptible to vancomycin [90]. Serious MRSA infections are increasingly difficult to treat using
current antibiotics [95]. While MRSA infections rates have recently trended downwards,
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community acquired MRSA infections are now more common requiring treatment using
antibiotics such as vancomycin [51, 96]. The concern is that vancomycin resistance seen in other
bacteria (including some S. aureus isolates) may be acquired by MRSA, thus leaving clinicians
without any viable treatment options [97]. In April 2014 Rossi et al. highlighted this problem
when they reported a case of MRSA resistant to vancomycin in Brazil [98]. There is a valid
concern that vancomycin-resistant MRSA could become predominant in the near future and such
infections may be untreatable. In 2012, there were an estimated 75,309 cases of invasive MRSA
with 9,670 resulting in deaths within the United States [99]. A 2011 study estimated that the case
fatality rate of invasive MRSA in the United States was about 25% [51] and another showed that
S. aureus bacteremia in New York City had a 30% mortality rate from 2002-2007
[18]. Researchers seeking new treatments for antibiotic-resistant bacteria have increasingly
begun to look towards bacteriophage as a viable option in treating these infections, either in
tandem with or as a replacement for antibiotics [64, 100].
Bacteriophages (phages) are viruses capable of infection and replication in bacterial
cells. Phages are the most common organism found on the planet and as such represent great
diversity in their overall host range [9, 10]. Since virus infectivity requires binding to a specific
receptor, phage are specific for a small host range and are thus unable to infect human cells.
Thus, the side effects associated with phage therapy of eukaryotic hosts are thought to be
minimal [12]. The idea of using phage as a potential therapeutic tool has been around for as long
as phage have been known to exist [12, 101] though some eastern European countries continued
using phage as medical treatments and in some countries physicians still regularly practice phage
therapy [66, 67]. Phage were used in the early 1900s to treat bacterial infections, but phage
treatment was largely abandoned in favor of antibiotics in the 1940s [102]. Although bacteria
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can evolve to escape from phage-mediated killing, the use of a biological agent such as phage
allows for evolution to also work in favor of phage re-acquiring the ability to lyse target cells
[72, 100, 103]. Thus, it is thought that phage therapy could be superior to antibiotic therapy in
terms of the ability of the treatment to evolve in response to the development of resistance by the
target bacterium. Off-target effects of antibiotic therapy can have detrimental effects on nonpathogenic normal flora, but such effects are expected to be minimal with phage therapy [12].
In this report, we describe the isolation of 12 phages with lytic activity towards human
MSSA/MRSA isolates. Virulent and temperate phages were found, isolated and purified using
MRSA strains as hosts. We analyzed the lytic host range and lytic ability of each phage using
spot tests and lytic culture assays of a panel of S. aureus and MRSA cultures isolated from
various human, livestock and environmental locations. In order to demonstrate the efficacy of
our phage for clearing MRSA, we used our new phage to decontaminate MRSA from fomites
and found a significant reduction in MRSA load from both a glass surface as well as fabric,
which could be associated with nosocomial transmission. Further, we found significant
reduction of MRSA loads when mixtures of MRSA isolates were treated with either single phage
or with phage cocktails. Our results suggest that phage can be used as an effective way to
decontaminate materials contaminated with MRSA.

Materials and Methods
Isolation of Staphylococcus aureus strains
Bacterial strains were isolated on Mannitol Salt agar (MSA) plates (Fluka
Analytical). Plaque assays and spot tests for host range were performed on Luria-Bertani (LB)
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agar (10g tryptone, 5g yeast extract, 5g NaCl, 1mL 2N NaOH, 12g/L agar). LB broth contained
10g tryptone, 5g yeast extract, 5g NaCl, and 1mL 2N NaOH per liter. Top LB agar contained
4g/L agar, supplemented with 4mM MgCl2 and 4mM CaCl2. Phage buffer was made with
100mM NaCl, 10mM MgCl2, 50mM Tris-HCl, and 0.01% gelatin (pH 7.5).
Some strains were acquired from the American Type Culture Collection (Manassas, VA,
USA) and others from BEI Resources (Manassas, VA). Additional strains of S. aureus were
obtained from athletic facilities, hospitals, nasal swabs, environmental sampling, and from
collaborators. To select for S. aureus, each sample was suspended in LB broth and thoroughly
vortexed. 10µL of each sample was spotted onto a MSA plate, streaked to isolation and
incubated at 37°C for 48h. Gram-staining, catalase and coagulase tube tests were performed on
single colonies isolated on MSA plates to confirm S. aureus (gram positive cocci positive for
catalase, coagulase and mannitol fermentation). Methicillin resistance was determined by plating
on MSA plates with 2 µg/mL oxacillin, followed by incubation at 37°C for 48h (note that
oxacillin resistance is considered to be equivalent to methicillin resistance in many studies; [89,
90]).
Isolation of bacteriophage
Virulent phage isolation
Samples were obtained from the environment and stored at 4°C until phage enrichment.
LB broth was added to dry samples and thoroughly vortexed to dislodge phage particles. An
equal volume of 2x LB broth was added to liquid samples. All samples were then filtered using
0.45µm filters to remove bacteria. The filtrate was then added to a 4h culture of five different
strains of S. aureus: M1, M5, S. aureus 29213, DH1 and HA1 (see Table 1). Samples were
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incubated overnight at 37°C shaking at 60rpm for phage enrichment. The overnight culture was
centrifuged for 12 min at 5,000xg to pellet bacteria, and then filtered using a 0.45µm filter.
100µL of phage sample was added to 100µL of bacteria and incubated overnight at 37°C before
adding to LB top agar for plaque production. Three rounds of successive plaque purifications
were performed to isolate each phage. The bacterial strain used to isolate each phage is indicated
in Table 2.
Temperate phage isolation
Log-phase S. aureus or MRSA sub-cultures were grown for 30 min at 37°C at 200rpm,
followed by exposure to mitomycin C (Sigma-Aldrich) at 0.5μg/mL for 8h at 37°C. Cells were
pelleted by centrifugation and supernatants passed through a 0.45μm filter and stored at 4°C until
plaque assays were performed, as above.
High titer phage lysates were prepared by adding host bacteria and phage into LB top
agar and overlaying onto LB agar plates. Overlays with near complete lysis, or a webbed plaque
distribution, were treated with 4ml of phage buffer and the top agar overlay was crushed,
followed by 90 min incubation at room temperature. Phage buffer was removed and centrifuged
at 5,000rpm for 10 min and filtered at 0.45μm to remove bacterial cells, then stored at 4°C with
chloroform. Phage stocks were tittered by limiting dilution, using a similar protocol as used for
plaque purification above.
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Host range analysis
Spot testing
Overnight cultures were prepared in LB medium and then sub-cultured by addition of
100µL to 3ml LB broth and grown at 37°C for 90min. 100µL of sub-culture was inoculated into
3mL of molten LB top agar and overlaid onto LB agar plates. Each overlay was allowed to
solidify for 15min. All phage lysates (original titers approximately 108pfu/mL) were diluted in
10 fold increments and 10µL of each dilution was spotted onto the bacterial overlay [91], dried,
then incubated at 37°C overnight. As a control, each bacterial strain was also mock infected with
sterile phage buffer. Results were analyzed based on detection of any lysis and further dilutions
were checked for single plaques to ensure phage lysis rather than bacteriocin induced lysis. All
spot tests were repeated in triplicate to confirm results.
Spectrophotometric assay of phage-treated liquid cultures
Overnight bacterial samples were sub-cultured in LB medium supplemented with 5mM
CaCl2 and MgCl2 until reaching an OD600 of 1.4 by shaking at 200rpm at 37°C. At that point,
20µL of bacteria was inoculated into 3.5mL LB medium. Phage samples were diluted to 108
pfu/mL in phage buffer. Bacterial samples were treated with 100µL of phage (or mock-treated
with sterile phage buffer alone) into 3.5mL of culture. Samples were removed at 2, 3, and 4h
after infection and the OD600 was measured on an Ultraspec 10 spectrophotometer (Amersham
Biosciences, Piscataway, NJ, USA) using growth medium as a blank. Experiments were run in
triplicate.
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Decontamination assays
Glass coverslip decontamination
Decontamination assays were performed to assess the ability of phage to clear MRSA
from surfaces. 22 x 22 mm glass coverslips were used to test decontamination on hard surfaces.
Coverslips were autoclaved and allowed to cool. 10µL of sterile milk was spread onto the
surface and allowed dry, giving the coverslips a better surface for bacterial adherence [88]. The
test MRSA strain was sub-cultured for 4h at 37°C to achieve logarithmic growth and then diluted
1:103, giving a final concentration of approximately 106 CFU/mL. 10µL of the culture was
spread onto the coverslips and allowed to dry at room temperature (approx. 30min). 100µL of
phage lysate was then added to the surface at a multiplicity of infection of 200-50,000 and
incubated at room temperature for 30min. A mock treatment was performed using sterile phage
buffer in place of phage lysate. To remove remaining bacteria from the surface, each coverslip
was placed in a sterile 50mL conical tube containing 500µL of LB medium and vortexed at highspeed for 10s. Serial dilutions of each test were then plated on LB agar and incubated overnight
at 37°C. Colonies were counted to determine bacterial load, and the ability of each phage to
decontaminate the surface was calculated by dividing the mock-treated bacterial loads by the
phage-treated bacterial loads.
Cloth decontamination
To test the utility of our phage for clearing MSSA/MRSA from items associated with
nosocomial transmission, we tested lab coat material which was composed of 35% cotton and
65% polyester. 1.5 x 1.5cm pieces were prepared and autoclaved to achieve sterility. MRSA
samples were sub-cultured for 4h to achieve logarithmic growth, then diluted 1:104 and 100µL
was added to the lab coat sample and allowed to remain for 30 min at 37°C. Our baseline
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bacterial load recovered from untreated cloth was ~1-5x104 CFU. 100µL of phage lysate was
then added and incubated at 37°C for 30min. Phage titers added to the cloth ranged from 1x107
to 1x108 PFU for a range of multiplicity of infection of 200 to 50,000. As a control, sterile phage
buffer alone was added as a mock treatment. Bacteria were removed by placing the cloth into
500µL LB medium followed by vortexing at high speed for 10s. The resulting medium was
serially diluted, then plated onto an LB agar plate and incubated at 37°C overnight; colonies
were counted the next morning. To determine the decontamination capability of the phage,
colony-forming units were calculated and mock-treated bacterial loads were divided by phagetreated bacterial loads. These assays were performed in triplicate.
Statistical analysis
Unpaired, one-tailed student’s t tests were performed in experiments from Figures 5, 6,
and 7 in order to determine if significant differences existed between phage-treated and mocktreated samples. A value of p < 0.05 was considered to be statistically significant.
Ethics Statement
Brigham Young University Institutional Review Board (IRB) approval was granted for
this study (protocol X14403). Informed written consent was obtained for each participant, and
minors were not included in this study. Other human samples were provided by collaborators
without any patient identifiers and were classified as exempt by the IRB.
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Results
Isolation of S. aureus and methicillin-resistant S. aureus (MRSA) strains
A diverse group of S. aureus and MRSA isolates were acquired during the course of these
experiments in order to be used as tools for phage discovery and characterization. Some isolates
were purchased from ATCC, some were acquired from collaborators, and others were isolated
from the environment including from human, animal, and environmental sources. The following
criteria were used to confirm isolation of S. aureus or MRSA: growth on mannitol salt agar
plates, ability to ferment mannitol, positive coagulase and catalase tests, and gram stains to
confirm gram-positive cocci. Growth in the presence of 2µg/mL oxacillin confirmed that some
isolates were MRSA. A summary of the S. aureus and MRSA isolates used in these studies is
found in Table 1. In total, 42 S. aureus strains were used including 30 MRSA and 12
methicillin-susceptible strains. 34 isolates were from human sources and 8 were from animal
sources.
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Table 1 S. aureus isolates
MSSA/MRSA isolates used in these studies. Isolates were confirmed as S. aureus or MRSA
as detailed in Methods. Methicillin resistance was tested by growth on MSA plates in the
presence of 2μg/mL oxacillin. ATCC = American Type Culture Collection, NS = human
nasal swab, HA = hospital acquired, DH = dog hair, CJ = raw chicken, RB = raw beef, TK =
raw turkey.
Strain ID
M1-9
SA 29213, 6538, 4651
MRSA 43300
USA300 LAC
USA300 strains 0114, CA-127, CO-34, GA92, NY-336, JE2
USA400 MW2
USA400 HFH-30364
NS 6, 15
NS 13-14, 16, 22-23
HA 1-5
DH 1-2
DH 3
CJ 11
CJ 9
RB 1
TK 11
TK 9

Source
Sports Training Center
Purchased from ATCC
Purchased from ATCC
Collaborator

Oxacillin
Resistant
Susceptible
Resistant
Resistant

Acquired from BEI

Resistant

Collaborator
Acquired from BEI
Nasal Swabs
Nasal Swabs
Hospital
Dog Hair
Dog Hair
Raw Chicken
Raw Chicken
Raw Beef
Raw Turkey
Raw Turkey

Resistant
Resistant
Resistant
Susceptible
Resistant
Resistant
Susceptible
Susceptible
Resistant
Susceptible
Resistant
Susceptible
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Isolation of S. aureus and/or MRSA-specific bacteriophage
Phages were isolated as described in methods, either from environmental samples or via
induction of prophages. In total we isolated 12 S. aureus-specific phages, all of which were
isolated on and have lytic activity against MRSA strains (see Table 2). 5 of these were temperate
phages induced from human S. aureus isolates by mitomycin C treatment. The remaining 7 were
virulent phages isolated from environmental samples. These samples were first suspended in LB
broth and then filtered to remove bacteria. This filtrate was then incubated with a mixture of 5
MSSA/MRSA strains to amplify any phage present. 6 of the 7 virulent phage originated from
poultry samples with the 7th originating from sewage influent. All phages were purified through
three rounds of plaque purification, with the S. aureus strain used listed in Table 2. Following
plaque purification, high titer phage stocks were produced and tittered by limiting dilution.
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Table 2 Phage Isolates
Phage isolates discovered in these studies. Temperate phages have a bipartite name
where the first part reveals the bacterial strain used for isolation and the second part
indicates the host strain. NS = human nasal swab, SEW = sewage influent, DH = dog
hair, CJ = raw chicken, CF = chicken feces.
Strain ID

Source

Isolating Strain

M1M5

Temperate/MRSA 5

M1

M1M4

Temperate/MRSA 4

M1

M1NS15

Temperate/NS 15

M1

M5NS22

Temperate/NS 22

M5

M5NS6

Temperate/NS 6

M5

SEW

Virulent/Sewage Influent

M1

CJ11

Virulent/Raw Chicken

M1

CJ12

Virulent/Raw Chicken

M1

CJ16

Virulent/Raw Chicken

DH1

CJ17

Virulent/Raw Chicken

DH1

CJ18

Virulent/Raw Chicken

DH1

CF6

Virulent/Chicken Feces

DH1
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Assessment of host range of phage isolates
One goal of this study was to determine the specificity of phage for particular
MSSA/MRSA isolates, with the expectation that some phage would have a broader tropism than
others due to presence/absence of phage receptor molecules or intracellular restriction
mechanisms. To assess the tropism of the phage described in Table 2, spot tests were performed
on plates containing lawns of various MSSA/MRSA isolates as described in Methods. Plates
were assessed for the lytic ability of each phage isolate by monitoring for clearing of bacterial
lawns (Table 3) and all spot tests were repeated to confirm the validity of the results. All
bacterial isolates shown in Table 1 were tested for host range, although many isolates were not
lysed by any of the phages and so those results are not shown in Table 3. Based upon spot
testing results, at least 6 unique phages were isolated: CJ12, SEW, M1M4, CJ17, a cluster
including M5NS6 and M5NS22, and a cluster including M1M5, CJ18, CJ11, CF6, M1NS15, and
CJ16. Interestingly, some members of the latter cluster (M1M5 and M1NS15) were found via
mitomycin C induction of prophage while the others were found as virulent phages (CJ18, CJ11,
CF6, CJ16).
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Table 3 Phage Host Range
Phages were assessed for host range by spot testing and plaque formation. Following
plaque purification, phages were tested for host range by spot testing on lawns of S.
aureus and MRSA isolates. Detection of any lawn clearing is indicated by an X. All
testing was performed in triplicate, and virus stocks were serially diluted to confirm
presence of phage lysis (discreet plaque formation) rather than bacteriocin activity.
Strain ID
M1

Virulent phages
SEW
X

CJ12
X

CJ16
X

CJ11
X

CJ18
X

Temperate phages
CF6
X

CJ17

M1M4
X

M1M5
X

M1NS15
X

X

M5
M7

X

X

X

X

X

X

X

X

X

X

DH1

X

X

X

X

X

X

X

X

X

X

NS13

X

HA1

X

HA3

M5NS6

M5NS22

X

X

X

X

X
X

X
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Phage M1M4 had the broadest host range, with lytic ability against 6 different bacterial
strains. CJ17 and the M5NS6 cluster had the narrowest host range, with only 2 different
bacterial strains lysed. Of the isolated phages, all had activity against human MRSA isolates,
possibly because a cocktail of human MRSA isolates were used to enrich phage in the early steps
of this study. We also noted that 3 bacterial strains (M1, M7, and DH1) were lysed by most of
the new isolated phages, possibly due to the lack of prophage in these isolates. The majority of
the bacterial isolates examined were not lysed by any of the phages. One possible explanation
for this finding is that half of the phages (6 of 12) were isolated from an animal source while
only 8 of the 42 S. aureus strains tested came from animal sources.
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Assessment of host range

Figure 5 Assessment of host range by lysis of bacterial cultures
Phages were added to log phase bacterial cultures to assess host range and to determine
the killing efficiency of the phages. Optical density was measured at 600nm to quantify cell
density of the culture. A) MRSA strain DH1 infected with phage strain SEW across a time
course. B) MRSA strain DH1 infected with phage strain CJ11 across a time course. C) A
variety of bacterial strains were challenged with different phage and OD600 readings were taken
at 4h. Results are reported in ∆OD600 units which were calculated as the difference between
the OD600 of mock-treated cultures (sterile phage buffer only) and phage-treated cultures. D)
Various combinations of bacterial strains were treated with either single phage strains or
combinations phage. In panels C and D, the percent difference in OD600 readings (phagetreated divided by mock-treated) is also shown. All experiments were performed in triplicate;
standard error is indicated. * p < 0.002 by student’s t test. # p < 0.01 by student’s t test when
evaluating phage treated vs mock treated samples.
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In order to confirm the host range results, and to determine the relative lytic ability of the
various phages, liquid bacterial cultures were exposed to phage and spec. assays were performed
in log phase cultures (Fig. 5). Since some bacterial isolates produce toxins, it is possible that
phage stocks contained such toxins which could lead to false positive results on a spot test. Such
toxins are expected to be too dilute to be effective in the large volumes used for a spec. assay but
could be active in the spot test procedure, thus the spot tests were diluted until single plaques
were visible. We found that changes in the optical density of bacterial cultures were routinely
noted at 180 and 240 min post-infection (Figs. 5A, B). In subsequent experiments, readings
were only taken at the 240 min time point. We calculated the difference in OD600 readings
between mock-treated and phage-treated cultures for a variety of phage and bacterial strain
combinations and results are reported in ∆OD600 units in Fig. 5C, D. We found significant
reductions in OD600 readings for many different combinations of phage and bacterial targets,
including significant differences when one phage was targeted to multiple bacterial isolates or if
multiple phages were used to target multiple bacterial isolates (Fig 5D).
Assessment of phage ability to decontaminate fomites
Nosocomial transmission of MSSA/MRSA is a major problem, especially when the
immunocompromised and those with underlying health issues become infected. We sought to
determine if our phages could effectively decontaminate fomites associated with nosocomial
transmission. We used the results of the spot tests to design combinations where the phages
were predicted to have a host range that would include the bacterial targets. Decontamination of
fabric was also analyzed as a more likely source of nosocomial transmission. We used glass
coverslips to represent decontamination of solid surfaces.
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To imitate a contaminated fomite we inoculated a single MRSA strain onto sterile cloth
(from a lab coat similar to one worn by clinicians) and then added a single phage and determined
the bacterial load following either phage treatment or mock treatment. Multiple phage
attachment incubation time points were tested to find the ideal time point for target cell lysis
(5min, 10 min, 15 min, and 30 min) and results are presented in Appendix Figure 1. The only
significant results detected were that a 30 min. phage cocktail treatment showed a significant
reduction in colony forming units (CFUs) in comparison to the 10 min. phage treatment on lab
coat fabric, and the 10 min. phage treatment showed a significant reduction in CFU in
comparison to the 30 min. phage treatment on glass coverslips. Subsequent experiments were
performed at 30 min. Mock treatments were performed using sterile phage buffer alone.
We found significant reductions in the numbers of MRSA CFUs in tests where one
phage/one MRSA was used to decontaminate lab coat fabric (Fig. 6). Decontamination of
MRSA strain M1 inoculated fabric with one of four phages yielded a 1-1.5 log reduction of
CFUs ml-1 compared to mock treated samples (Fig. 6A). Each different phage treatment had a pvalue < 0.01. MRSA DH1 was similarly inoculated and treated with phages (Fig. 6C) and
resulted in 0.5-1 log reductions in CFUs in each test with a p-value < 0.05.
We inoculated sterile glass coverslips with MRSA (see Methods) and then treated with
singular phages or mock treatments and measured the ability to decontaminate bacteria (Fig. 6B,
D). Glass slides inoculated with MRSA strain M1 and treated with singular phage showed
highly significant reductions in CFUs (p < 0.005) compared to mock treatments (Fig. 6B). Each
phage treatment yielded at least a 1.5 log reduction in CFUs with two phages nearly achieving a
2 log reduction. Coverslips inoculated with MRSA strain DH1 also showed significant decreases
in CFUs as compared to the mock treatment (Fig. 6D), with the exception of M1M4 treatment.
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CJ11 treated coverslips achieved a 0.5 log reduction (p < 0.02), while SEW and CJ12 achieved a
1 log (p < 0.01) and 1.5 log reduction (p < 0.007), respectively.
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Decontamination, single phage

Figure 6 Decontamination of lab coats and glass coverslips
MRSA samples were inoculated onto either lab coat fabric or glass coverslips and
then exposed to either a single phage or a mock phage treatment (sterile phage buffer only).
The multiplicity of infection ranged from 200 to 50,000. Bacteria were recovered and viable
bacterial counts were determined by serial dilution and growth on LB agar plates. Results
are reported as colony-forming units ml-1 A) MRSA strain M1 treated with either SEW,
M1M4, CJ11 or CJ12 recovered from lab coat fabric. B) MRSA strain M1 treated with
either SEW, M1M4, CJ11 or CJ12 recovered from glass coverslips. C) MRSA strain DH1
treated with either SEW, M1M4, CJ11 or CJ12 recovered from lab coat fabric. D) MRSA
strain DH1 treated with either SEW, M1M4, CJ11, or CJ12 recovered from glass
coverslips. Assays were performed in triplicate; standard error is indicated. * p < 0.05 by
unpaired, one-tailed student’s t test when evaluating phage-treated vs mock-treated samples.
# p < 0.005 by same student’s t test.
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We combined phages M1, M1M4, CJ11, and CJ12 to create a phage cocktail to measure
potential synergistic ability to decontaminate MRSA from lab coat material or glass coverslips
(Fig. 7). The phage cocktail was designed to include the most efficiently lytic phages as well as
those with the broadest tropism. Using the phage cocktail we found significant reductions in
CFUs when decontaminating either lab coat fabric (Fig. 7A) or glass coverslips (Fig. 7B). In
treating the lab coat fabric we observed a nearly 2 log reduction in CFUs for both M1 and DH1
strains. In studies using MRSA strain DH1, we found a highly significant decrease in CFUs on
fabric with a p value < 0.008 (Fig. 7A), similar to the phage cocktail treatment of MRSA strain
M1 on a glass coverslip with a p value < 0.003 (Fig 7B).
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Decontamination, Phage cocktail

Figure 7 Decontamination of lab coats and glass coverslips with a phage cocktail
MRSA samples were inoculated onto either lab coat fabric or glass coverslips and then
exposed to a phage cocktail consisting of SEW, M1M4, CJ11, CJ12, or mock phage treatment
(sterile phage buffer only). The combined multiplicity of infection ranged from 300 to
1,300. Bacteria were recovered from treated materials and viable bacterial counts were
determined by serial dilution and growth on LB agar plates. A) MRSA strain M1 and DH1
treated with phage cocktail or mock treatment recovered from lab coat fabric. B) MRSA strain
M1 and DH1 treated with phage cocktail or mock treatment recovered from glass coverslips.
Assays were performed in triplicate; standard error is indicated. * p < 0.05 by unpaired, onetailed student’s t test when evaluating phage-treated vs mock-treated samples. # p < 0.005 by
same student’s t test.
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Discussion
In this study, we isolated 12 new phages with lytic activity against S. aureus and MRSA.
We determined the host range of these phages by both spot testing and spec. assays of phagetreated bacterial cultures. We then examined the ability of single phages or phage cocktails to
decontaminate MRSA from a glass surface as well as from fabric. We found that our phages
were able to significantly reduce MRSA growth in culture, and that they were able to
significantly reduce colony-forming units of human MRSAs from both glass and fabric.
The host range tests carried out in these studies showed that our newly isolated phage
tended to have greater lytic activity against human S. aureus strains as compared to non-human
isolates, and to also lyse MRSA more commonly than methicillin-susceptible S. aureus. Most of
our virulent phage isolates were found in sources related to chickens. Phage isolated from
chicken sources would not necessarily be predicted to have activity against MRSA or human S.
aureus isolates. However, these findings may be related to the protocol used to initially enrich
phage, wherein 5 S. aureus strains were used: 4/5 was MRSA and 4/5 was human S. aureus
isolates. Other phage may have been present during enrichment, but we selected for those with
lytic activity against human MRSA in our enrichment protocol.
Measurement of the optical densities of phage-treated MRSA cultures revealed that very
efficient lysis occurred. The density of phage-treated cultures after 4h was essentially the same
as 2h. After comparing the results of the spot tests and spec. assays, we found that the results
were mostly in agreement with one another. Some anomalies were seen in this comparison, such
as when spot tests indicated lytic ability for a given phage/bacterial strain but culture assays
failed to show significant lysis. Two examples are shown in Fig 5C (e.g., SEW and CJ12
treatment of isolate HA1). When we tested more challenging scenarios for phage reduction of
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bacterial samples (e.g., one phage targeted to 3-4 bacterial strains in Fig. 5D) we still detected
significant reductions in bacterial cell density. The cell density was higher in such experiments,
despite the fact that spot testing predicted that all bacterial strains could be lysed. We partially
attributed these findings to MRSA strain HA1, which was not lysed efficiently in culture assays.
When strain HA1 was removed from one such experiment, the cell density dropped (Fig. 5D and
data not shown) indicating that HA1 was less susceptible to clearing in a culture assay.
We opted to use glass as a model test surface for MRSA decontamination, as has been
tested previously by others [88]. Significant reductions in bacterial CFUs were detected in
nearly all experiments when using either glass or fabric. One experiment failed to show a
significant reduction for phage strain M1M4 (see Fig. 6D), but this strain was discovered as a
temperate phage and so the lytic potential is expected to be less than that seen for virulent
phages. Since M1M4 had the broadest host range of our phages, we still included this phage in
subsequent testing. Many decontamination experiments showed a reduction in CFUs greater
than 1 log, and occasionally 2 log reductions were seen. Cocktails of phage were typically more
effective at decontaminating MRSA than single phage.
We conclude that we have isolated at least 6 unique phages with lytic activity against
human MRSA isolates. These phages have robust activity in both liquid culture and in
decontaminating hard surfaces and fabrics associated with nosocomial transmission. Our future
plans include further characterization of these phages by genome sequencing and transmission
electron microscopy, and further testing for decontamination potential under varying
circumstances.
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Discussion
Phages have some very attractive attributes for medical phage therapy and especially for
fomite decontamination. The results of the preceding research show that fomite decontamination
using phages is a viable option. However, increased phage host range and lytic ability need to be
achieved before widespread disinfectant use can occur. The three-fold hypothesis stated that
phages could be found and isolated into pure strains, the host range and lytic efficiency for each
of the phage could be identified, and using phages to decontaminate fomites is possible and
reduced bacterial loads from common fomites harboring MSSA or MRSA was achieved. The
phage cocktail treatments achieved 2 log reductions in bacterial load and show promise for future
use in cleaning fomites.
Using induction and enrichment techniques, 15 phage isolates were initially found. Three
of the phages lacked the ability to produce a strong lytic infection. They could not be maintained
in high enough titers to perform all three steps of plaque purification and were subsequently
abandoned. In addition, 42 S. aureus isolates were found and all were used in determining the
phage host ranges.
Through host range tests and lytic ability the phages were assed for future use in
decontamination assays. The spot test was designed to analyze each phage’s ability to lyse each
of the 42 S. aureus isolates. Each phage isolate was able to lyse at least 2 primary S. aureus
isolates. Unfortunately, none of the phages were able to lyse any USA300 and USA400
strains—much lower than initial expectations. This lack of lytic ability towards the most
common MRSA isolates in the United States limits the efficacy of the phages use outside of the
lab. However, in the future, consistent passaging of the phages in the presence of the USA300
and USA400 strains can increase the host range to eventually lyse these strains [70, 73]. Using
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this method, future research should be able to create a phage cocktail with a much larger host
range than the current host range of the cocktail presented in this document.
Based on host range results the phages were categorized into groups with similar patterns
indicating that there were at least six different phage strains isolated. CJ12, SEW, and M1M4 all
had unique host ranges, while M1M5 and CJ18; CF6, M1NS15, CJ16, CJ17, and CJ11; M5NS6
and M5NS22 were grouped together respectively. The differences in host range did allow us to
combine the phage in a cocktail to create a phage lysate with a host range larger than any single
phage. The phage host ranges only included human S. aureus strains rather than the non-human
isolates. This oddity was not predicted based on the locations where most of the virulent phages
were isolated; the raw meat sources would not necessarily indicate a preference towards lysis of
human strains of S. aureus but rather the raw meat strains. The limited host range may be related
to the protocol used to enrich the phages [104]; wherein five different S. aureus strains were
used. The enriching hosts were 4/5 MRSA and 4/5 human S. aureus isolates. Other phages may
have been present during enrichment, but by using mostly human MRSA strains the enrichment
may have inaδvertently enriched only the phages with lytic activity against human MRSA and
without any lytic activity against the raw meat S. aureus. Secondly, the enrichment process did
not use any USA300 or USA400 strains potentially leading to enrichments without phages
ability to lyse the most common MRSA strains.
Optical density (OD) differences in bacterial growth were observed between phage
treated and mock treated liquid MRSA cultures. In most cases the spec. assay results reinforced
the host range results. HA1 lysis proved to be the exception with phages being unable to
significantly reduce bacterial growth (Fig. 5C). CJ12 and SEW treatment reduced MRSA cell
density by less than 1 OD600. Other MRSA strains were significantly reduced by phage
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treatment. HA1 may have stronger defense mechanisms for protection of phage resulting in
decreased phage lysis and thus positive results during spot testing, but little other lysis in liquid
cultures [11].
When tested with more challenging scenarios for phage reduction of bacterial samples
(e.g., one phage targeted to 3-4 bacterial strains in Fig. 5D), we still detected significant
reductions in bacterial cell density. The cell density was higher in such experiments compared to
singe phage-single host pairings. All host strains in the S. aureus cocktail were within each
phage’s host range, but increased cell density may be partially attributed to HA1’s low lysis rates
in liquid cultures. When strain HA1 was removed from one such experiment, the cell density
dropped (Fig. 5D and data not shown) indicating that HA1 was less susceptible to clearing in a
culture assay. Importantly, single phage strain treatments were able to show significant
reductions in cell density of at least 0.2 OD600, indicating that phage treatment against
contamination with multiple MRSA strains can still be reduced using phage treatment.
The final aim was to realistically simulate fomites in hospital settings and use the phages
to decrease MRSA load. Lab coat material mimicked the passage of S. aureus from patient to
doctor to other patients. Using small strips of lab coat material we showed approximately two
log reductions in bacterial CFUs with all phages used. CJ12 was the most efficient single phage
in reducing bacterial load on lab coat material with reductions of about 2 logs against both DH1
and M1 (Fig 6). When phages SEW, M1M4, CJ11, and CJ12 were combined into a cocktail,
synergistic reductions in CFUs were observed. Approximately two log CFU reductions were
observed in every instance when using the phage cocktail to decontaminate lab coat fabric (Fig
7A).
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Glass coverslips provided a model system for simulating hard surface contamination in
hospital settings and has previously been used for bacterial decontamination using phage [88].
The glass surface was thought to be a more hospitable environment for the phage than fabric, and
when compared to lab coat material decontamination we expected to see higher levels of
bacterial load reduction. Unexpectedly, we didn’t see much difference between the two
decontamination surfaces indicating that neither surface was better or worse for phage use.
Using the glass slides we did detect significant reductions in bacterial CFUs in nearly all
experiments (Fig. 6 B & D). M1M4 had the broadest host range; however, its lytic ability was
not as robust as some of the other phages (Fig 6 B & D). Lack of robust lysis from M1M4 is not
unusual because M1M4 is a known temperate phage and likely entered the lysogenic cycle,
halting cell lysis. Despite being a known temperate phage it still significantly reduced M1
bacterial load on the glass slides. SEW and CJ12 phages were able to show significant
reductions in all the experiments on glass slides. Similar to lab coat fabric decontamination we
did see synergistic reduction in MRSA CFUs (Fig. 7B).
The phage cocktail showed a significant 2 log decrease in bacterial loads on fomites.
Despite the significant reduction, using the phage cocktail as a decontaminate for MRSA is
likely still insufficient reason to warrant switching from cleansing wipes able to reduce bacterial
loads 5 logs [61]. An important factor which may be playing a role in preventing greater log
reductions in MRSA CFU may be the temperate natures of the phages [101]. Based on
morphological data not shown in this thesis I suspect that most of the phage may belong to the
Siphoviridae class of phages. Siphoviridae are typically temperate phage and as such may be
entering the lysogenic cycle during the decontamination test, reducing the ability of the phage to
decontaminate a surface. Lysogen formation should be tested in the future by treating surviving
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MRSA colonies again with the same phage. Phages with higher lytic ability and less
preponderance to enter the lysogenic cycle can also be selected for by continuous passaging.
The phages within the cocktail could be selected for increased host ranges using previously
discussed methods and increased lysis efficiency [76]. If the host range and lytic efficiency is
increased to 5-6 log reductions of MRSA load, the phage cocktail would become a viable
cleanser for hospital surfaces.
Future experiments are needed to more fully characterize the phages through gene
sequencing. Phage DNA will be isolated and used for Sanger sequencing to identify novel
strains of phage. Once novelty has been assured more thorough sequencing using next
generation sequencing can take place. The resulting genetic data will be annotated and analyzed
for interesting phage genes. Genes of special interest are lysogenic genes, S. aureus virulence
genes, and antibiotic resistance genes. Ideal phages will not harbor any of these genes.
S. aureus biofilms also present a significant problem because of their formation on
fomites inserted into the body. This introduces S. aureus into the body and acts as a reservoir for
infections. A follow-up project we are working on uses bacteriophage and silver nanoparticles to
eliminate S. aureus biofilms. Silver nanoparticles have previously been shown to have a
bactericidal effect and can reduce S. aureus biofilms [44]. Biofilm forming S. aureus will be
identified using three different techniques: congo red-agar biofilm detection, PCR of biofilmassociated genes, and crystal violet staining of biofilms. S. aureus colonies on congo red-agar
turn black when producing a biofilm. Initial testing shows that 98% of the 42 S. aureus strains
form at least a weak biofilm. Initial testing has also shown that many of the S. aureus strains
harbor known biofilm forming genes, for example icaD. We will also use crystal violet staining
to measure the efficacy of biofilm removal using phage therapy, silver nanoparticle treatment, or
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a combined approach, but as of yet have not yet begun working on this aspect of the project. The
end goal of the project is a decrease in biofilm formation when both phages and silver
nanoparticles are present.
An additional follow-up research project will look at S. aureus contamination in raw
meat. Many S. aureus strains found in meat are multi-antibiotic resistant and represent further
danger to the community. The follow-up project will look at the prevalence of MRSA
contaminating raw meats with the endpoint of identifying contamination rates in raw beef,
poultry, and pork. Minimum inhibitory concentrations for eight common antibiotics will also be
performed to identify multi-antibiotic resistant strains and their prevalence. Each S. aureus
isolate will also be genotyped for specific virulence factors, biofilm production, and immune
evasion genes. As we move forward with research into MSSA, MRSA and S. aureus phages we
hope to find new methods for treating MRSA infections and controlling its transmission through
fomite decontamination.
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Appendix

Supplementary Figure 1 Time course decontamination of lab coats and glass coverslips
A decontamination time course assay was done to identify the optimal time to expose the bacterial to
phage before recovering cells. MRSA samples were inoculated onto either lab coat fabric or glass
coverslips and then exposed for 5 min., 10 min., 15 min. or 30 min. to either a phage cocktail or a
mock phage treatment (sterile phage buffer only; results not shown). The multiplicity of infection
ranged from 200 to 50,000. Bacteria were recovered and viable bacterial counts were determined by
serial dilution and growth on LB agar plates. Results are reported as colony-forming units ml-1 A)
MRSA strain DH1 inoculated onto lab coat fabric and then treated with a phage cocktail of SEW,
M1M4, CJ11 and CJ12. The 30 min. phage treatment showed a significant reduction in CFUs in
comparison to the 10 min. phage treatment. B) MRSA strain DH1 inoculated onto glass coverslips
and then treated with a phage cocktail of SEW, M1M4, CJ11 and CJ12. The 10 min. phage treatment
showed a significant reduction in CFU in comparison to the 30 min. phage treatment. Assays were
performed in triplicate; standard error is indicated. * p < 0.05 by unpaired, one-tailed student’s t test
when evaluating the various time points relative to each other.
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